NDT Advance Access published online on March 19, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh222
© 2004 by European Renal Association - European Dialysis and Transplant Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Jefferson Medical College, Philadelphia, PA, USA
* To whom correspondence should be addressed. E-mail: Beckie.Michael{at}jefferson.edu.
Background. A previous single dose placebo-controlled double-blinded trial showed an extremely low (0.4%) intolerance rate of sodium ferric gluconate complex (SFGC) in SFGC-naive haemodialysis patients. No large prospective trials have assessed the safety of SFGC during repeated exposure in the outpatient haemodialysis setting. Methods. Chronic haemodialysis patients completing the single-dose trial of SFGC were eligible to participate in this prospective, multicentre, open-label, long-term evaluation of SFGC, designed to record adverse events occurring up to 72 h post-dose. Patients received as many as 20 ampules (1250 mg total) of SFGC at an investigator-determined dose and rate over a 9 month evaluation period. Results. Among 1412 enrolled patients at 54 centres, 1321 received 13 151 infusions of SFGC. Most doses (94.8%) were Conclusions. Repeated doses of SFGC are very well tolerated in haemodialysis patients. No life-threatening events were observed in over 13 000 doses administered. Administration of SFGC to patients using ACEI is safe and does not increase the incidence or severity of adverse events to SFGC.
Accepted February 18, 2004
Original Article
Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety
2 Washington University School of Medicine, St Louis, MO, USA
3 Albert Einstein College of Medicine/Monte.ore Medical Center, Bronx, NY, USA
4 Watson Laboratories, Morristown, NJ, USA
5 University of Alabama at Birmingham, Birmingham, AL, USA
Abstract 
125 mg and the majority were given over 10 min. Infusion rates ranged from <5 to 125 mg/min. There were no life-threatening events. Fifty-one patients (3.9%) experienced an adverse event, possibly related to SFGC. Of these, one experienced a serious event (hypotension). Five patients (0.4%) experienced an event that precluded SFGC readministration: pruritus (three), vasodilatation (one) and loss of taste (one). Among 372 patients (28.2%) receiving angiotensin-converting enzyme inhibitor (ACEI) therapy, adverse events were neither more common nor more severe than in the other patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. W. Coyne, T. Kapoian, W. Suki, A. K. Singh, J. E. Moran, N. V. Dahl, A. R. Rizkala, and the DRIVE Study Group Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J. Am. Soc. Nephrol., March 1, 2007; 18(3): 975 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufman Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, February 1, 2007; 12(2): 231 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Saadeh and G. Srkalovic Acute Hypersensitivity Reaction to Ferric Gluconate in a Premedicated Patient Ann. Pharmacother., December 1, 2005; 39(12): 2124 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kalantar-Zadeh, D. L. Regidor, C. J. McAllister, B. Michael, and D. G. Warnock Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3070 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Michael The safety of sodium ferric gluconate complex in haemodialysis patients has been extensively evaluated Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1770 - 1770. [Full Text] [PDF]
|
|
|
|
|
|
B. A. J. Walters and D. B. Van Wyck Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1438 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Aronoff Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106. [Full Text] [PDF]
|
|